Duncan Whitney

Duncan Whitney has a diverse work experience in the field of diagnostics and genomics. Duncan is currently serving as the Chief Scientific Officer at Gregor Diagnostics since March 2022. Prior to that, they worked at Johnson & Johnson as the Head of Early Detection Lung Cancer Initiative from September 2018 to September 2021.

Before joining Gregor Diagnostics and Johnson & Johnson, Duncan Whitney held various leadership positions in notable companies. Duncan was the VP Molecular Diagnostics at Curis from July 2017 to October 2018. Duncan also served as the VP of Discovery Research at Veracyte, Inc. from September 2014 to June 2017 after their acquisition of Allegro Diagnostics, where Duncan served as the SVP & CSO of Research & Development from October 2009 to September 2014.

Duncan Whitney's career includes other important roles such as Chief Scientific Officer at Progenika Inc. from October 2007 to August 2008, VP of Research & Development at U.S. Genomics from September 2005 to September 2007, and VP of Process Development at Exact Sciences from February 2000 to August 2005.

Their extensive experience in the field also includes a senior director position at ABI-PerSeptive Biosystems from 1990 to 1999, showcasing their long-standing commitment to the industry.

Duncan Whitney holds a PhD in Chemistry which they obtained from the Massachusetts Institute of Technology between 1983-1987. Prior to that, Duncan completed their Bachelor's Degree in Chemistry at Colby College, although the specific years are not provided.